 | • レポートコード：D0-MOR-AP1138 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、甲状腺がん治療の世界市場について調査・分析した資料で、甲状腺がん治療の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The thyroid cancer therapeutics market is expected to register a CAGR of 12.4% during the forecast period. Thyroid cancer is a type of cancer that develops in the thyroid gland and can spread to other parts of the body. The thyroid gland is a butterfly-shaped gland that wraps around the front of the windpipe. The thyroid gland is a part of the endocrine system, that produces and controls the hormones in the body. The thyroid gland produces hormones that regulate blood pressure, heart rate, energy metabolism, and body temperature. There are four main types of thyroid cancer, classified based on the types of cells where cancer begins papillary, follicular, medullary and anaplastic thyroid cancer. Papillary thyroid cancer is the most common type of thyroid cancer, accounting for about 80% of all cases. Thyroid cancer typically doesn’t cause any signs or symptoms early in the disease. As thyroid cancer grows, it may cause a lump (nodule) that can be felt through the skin on the neck, difficulties in swallowing, pain in neck and throat, and swollen lymph nodes in the neck.
As per the American Society of Clinical Oncology (ASCO) in 2019, approximately 14,260 men and 37,810 women in the United States were diagnosed with thyroid cancer. It is the most common cancer in women between 20 to 34 years of age and women are more likely to develop thyroid cancer than men. About 2% of cases occur in children and teens. In addition, rise in thyroid cancer can be attributed to family history of goiter, exposure to radiation and some hereditary syndromes.
Furthermore, rising cases of thyroid cancer worldwide, increasing government funds, and growing awareness regarding thyroid cancer treatment options are the key driving factors in thyroid cancer therapeutics market.
Key Market Trends
Drugs Segment is Expected to Hold a Major Market Share in the Thyroid Cancer Therapeutics Market
Drugs segment holds a significant market share in the thyroid cancer therapeutics market and is anticipated to show a similar trend over the forecast period owing to an increase in the use of combination drugs as these are more effective and helps to prevent cancer progression. For instance, in 2018, the FDA approved the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of anaplastic thyroid cancer. These combination drugs prevent the growth of cancer cells and reduce the development of drug resistance.
As per the Thyroid Cancer Survivors’ Association, estimates that there will be about 52,890 new cases of thyroid cancer in the United States in 2020, compared to 52,070 cases in the year 2019. Deaths due to thyroid cancer are expected to increase slightly to 2,180 in the year 2020, from 2,170 in 2019, 2,060 in 2018, and 2,010 in 2017. Moreover, increasing incidence and prevalence of thyroid cancer cases and promising pipeline drugs for the treatment of thyroid cancer are the key driving factors in the drugs segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global thyroid cancer therapeutics market due to increasing cases of thyroid cancer in this region. According to the Centers for Disease Control and Prevention (CDC), every year about 35,000 women and 12,000 men suffer from thyroid cancer, and more than 1,100 women and 900 men die from the disease. Moreover, in the United States in 2016, it is estimated that about 64,000 new patients were diagnosed with thyroid cancer. Furthermore, the presence of top pharma and biotech companies that are involved in the development of new therapies and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.
Competitive Landscape
The Thyroid Cancer Therapeutics Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market include Sanofi (Genzyme Corporation), Exelixis, Inc, Medtronic Plc, Eisai Co., Ltd, Bayer AG, AbbVie Inc, Novartis AG, Pfizer Inc, Mylan N.V. and Bristol-Myers Squibb Company among others.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence and Incidence Rates of Thyroid Cancer
4.2.2 Growing Awareness about Treatment Options for Thyroid Cancer
4.2.3 Rising Government Funds and Favorable Reimbursement Policies
4.3 Market Restraints
4.3.1 Introduction of Generic Drugs Due to Patent Expiry of the Branded Drugs
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Papillary thyroid cancer
5.1.2 Follicular thyroid cancer
5.1.3 Medullary thyroid cancer (MTC)
5.1.4 Anaplastic thyroid cancer
5.1.5 Hurthle cell cancer
5.2 By Therapy
5.2.1 Drugs
5.2.2 Radiation Therapy
5.2.3 Other Therapies
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Sanofi (Genzyme Corporation)
6.1.2 Exelixis, Inc
6.1.3 Medtronic Plc
6.1.4 Eisai Co., Ltd
6.1.5 Bayer AG
6.1.6 AbbVie Inc
6.1.7 Novartis AG
6.1.8 Pfizer Inc
6.1.9 Mylan N.V.
6.1.10 Bristol-Myers Squibb Company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS